
Filippo G Giancotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2654012/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports, 2022, 39, 110595.	2.9	25
2	The Hippo pathway mediates Semaphorin signaling. Science Advances, 2022, 8, .	4.7	6
3	Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype. Prostate Cancer and Prostatic Diseases, 2021, 24, 1080-1092.	2.0	15
4	Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. Molecular Cancer Therapeutics, 2021, 20, 1584-1591.	1.9	11
5	A heterotrimeric SMARCB1–SMARCC2 subcomplex is required for the assembly and tumor suppression function of the BAF chromatin-remodeling complex. Cell Discovery, 2020, 6, 66.	3.1	10
6	The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell, 2019, 36, 139-155.e10.	7.7	131
7	Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma. Trends in Cancer, 2019, 5, 440-455.	3.8	29
8	Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphoma. Science Translational Medicine, 2019, 11, .	5.8	51
9	Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell, 2019, 35, 347-367.	7.7	533
10	Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nature Cell Biology, 2018, 20, 966-978.	4.6	186
11	Cancer: a new role for non-canonical Hippo signaling. Cell Research, 2017, 27, 459-460.	5.7	4
12	Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses <i>NF2</i> Loss–Driven Tumorigenesis. Molecular Cancer Therapeutics, 2017, 16, 1693-1704.	1.9	31
13	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications, 2016, 7, 13131.	5.8	140
14	Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell, 2016, 166, 47-62.	13.5	194
15	Alan Hall 1952–2015. Nature Cell Biology, 2015, 17, 839-840.	4.6	1
16	<i>NF2</i> Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discovery, 2015, 5, 1178-1193.	7.7	107
17	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPKÂsignalling. Nature Cell Biology, 2015, 17, 81-94.	4.6	97
18	Molecular insights into <i>NF2</i> /Merlin tumor suppressor function. FEBS Letters, 2014, 588, 2743-2752.	1.3	154

FILIPPO G GIANCOTTI

#	Article	IF	CITATIONS
19	Deregulation of cell signaling in cancer. FEBS Letters, 2014, 588, 2558-2570.	1.3	103
20	Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16532-16537.	3.3	49
21	Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus. Cancer Cell, 2014, 26, 48-60.	7.7	198
22	Mechanisms Governing Metastatic Dormancy and Reactivation. Cell, 2013, 155, 750-764.	13.5	477
23	β4 Integrin signaling induces expansion of prostate tumor progenitors. Journal of Clinical Investigation, 2013, 123, 682-99.	3.9	74
24	The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites. Cell, 2012, 150, 764-779.	13.5	365
25	Integrin β4 Signaling Promotes Mammary Tumor Cell Adhesion to Brain Microvascular Endothelium by Inducing ErbB2-Mediated Secretion of VEGF. Annals of Biomedical Engineering, 2011, 39, 2223-2241.	1.3	67
26	Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus. Cell, 2010, 140, 477-490.	13.5	287
27	Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. Journal of Clinical Investigation, 2009, 119, 252-66.	3.9	216
28	Targeting integrin β4 for cancer and anti-angiogenic therapy. Trends in Pharmacological Sciences, 2007, 28, 506-511.	4.0	119
29	Adhesion of wild type and integrin signaling defective mammary tumor cells to microvascular endothelium in vivo. FASEB Journal, 2007, 21, A487.	0.2	0
30	β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. Cell, 2006, 126, 489-502.	13.5	418
31	Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. Journal of Cell Biology, 2005, 171, 361-371.	2.3	174
32	Integrin signalling during tumour progression. Nature Reviews Molecular Cell Biology, 2004, 5, 816-826.	16.1	1,317
33	Integrin β4 signaling promotes tumor angiogenesis. Cancer Cell, 2004, 6, 471-483.	7.7	212
34	Positional Control of Cell Fate Through Joint Integrin/Receptor Protein Kinase Signaling. Annual Review of Cell and Developmental Biology, 2003, 19, 173-206.	4.0	344
35	A Structural View of Integrin Activation and Signaling. Developmental Cell, 2003, 4, 149-151.	3.1	101
36	EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes. Journal of Cell Biology, 2001, 155, 447-458.	2.3	303

FILIPPO G GIANCOTTI

#	Article	IF	CITATIONS
37	Complexity and specificity of integrin signalling. Nature Cell Biology, 2000, 2, E13-E14.	4.6	225
38	Cell cycle and adhesion defects in mice carrying a targeted deletion of the integrin β4 cytoplasmic domain. EMBO Journal, 1998, 17, 3940-3951.	3.5	159
39	?3?1-integrin as a critical mediator of the hepatic differentiation response to the extracellular matrix. Hepatology, 1998, 28, 1095-1104.	3.6	50
40	Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell, 1990, 60, 849-859.	13.5	781